Semaglutide 7mg tablets and weight loss: separating fact from confusion

The 7mg strength is Rybelsus territory, not a weight-loss dose

The misconception is understandable. Semaglutide is the active ingredient in several different medicines, and a quick search can easily surface the 3mg, 7mg and 14mg tablet strengths associated with it. Those are Rybelsus doses, prescribed to adults managing type 2 diabetes. The 7mg tablet sits in the middle of the Rybelsus schedule as a step-up from the starter dose, it has nothing to do with the obesity treatment pathway.

This matters practically, not just technically. Rybelsus is not licensed for weight loss in the UK, and the NHS semaglutide guidance draws a clear line between the diabetes and weight-management uses. A prescriber cannot legally issue Rybelsus for weight loss; doing so would be prescribing outside its licensed indication. Anyone selling a 7mg semaglutide tablet and presenting it as a weight-loss medicine should prompt immediate caution.

It is worth sitting with this for a moment, because a lot of people arrive at this question having seen the 7mg strength mentioned in a forum or social media post. The information circulating there conflates the two medicines. The dose ladder for weight management is completely separate, and it starts at a much lower strength than 7mg.

If you want to explore the full picture of oral semaglutide, our semaglutide tablets overview covers the licensed options clearly.

What the actual oral weight-loss dose schedule looks like

The Wegovy tablet was approved by the MHRA on 11 June 2026, making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. Its dose schedule runs 1.5mg, 4mg, 9mg and up to 25mg, a separate ladder entirely from Rybelsus, with a much higher ceiling.

Each step requires at least a month before moving to the next, and your prescriber decides the pace based on how your body is responding. The 25mg tablet is the maintenance dose. People already established on the 2.4mg weekly Wegovy injection may, subject to clinical assessment, move directly to the 25mg tablet, though that transition is always a decision for the prescriber, not the patient.

Taking the tablet correctly matters for how much semaglutide your body actually absorbs. It needs to be swallowed whole, first thing in the morning, with a small amount of plain water (up to around 120ml), before anything else passes your lips, including coffee. A wait of at least 30 minutes follows before food, drink or other oral medicines. That routine is non-negotiable for the medicine to work as the trial data showed.

The clinical evidence for the Wegovy tablet comes from the OASIS 4 phase-3 trial, in which participants without diabetes lost an average of around 13.6% of their body weight over 64 weeks. Among those who stayed fully adherent to treatment, the average reached roughly 17%. Those results were the basis for the MHRA's approval. You can read more about how the tablet compares to the injection on our Wegovy tablets page.

Storage, practicalities and who this medicine suits

One feature that separates the Wegovy tablet from the injection is storage. No refrigerator required, the tablets are kept at room temperature, which simplifies travel and everyday routine considerably. For someone who found the prospect of injections off-putting, or who travels frequently, that is a meaningful difference.

The licensed eligibility criteria mirror those for the injectable Wegovy: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes or raised cholesterol. BMI thresholds are set 2.5 kg/m² lower for some ethnic backgrounds under UK guidance. Suitability is always confirmed by a prescriber reviewing your individual circumstances, BMI alone is not the whole picture.

The most common side effects seen in the OASIS 4 trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation appeared more often in the semaglutide group than placebo, though most were mild to moderate and tended to ease over time. The same profile applies to the injection, but some people find the tablet's slower absorption gentler on the stomach in early weeks. The MHRA's Wegovy approval communications contain further detail on the safety profile across semaglutide presentations.

The Wegovy tablet is not currently available on the NHS, a NICE appraisal would need to happen first. For now it is a private prescription only. If you would like to understand what that involves, our Wegovy pill overview goes into the full detail, and our Wegovy tablet pricing page explains what a legitimate private prescription actually includes. The NHS does not yet have a pathway for it, but private treatment through a regulated pharmacy is a well-established route for people who are clinically suitable and do not want to wait.

If you're not sure which treatment option fits your situation, our weight-loss treatments overview lays out what is licensed, what the evidence shows, and how a clinical assessment helps narrow it down. When you're ready, a free consultation with our prescribers is the natural next step, and if oral semaglutide is on your radar, our guide to semaglutide tablets for weight loss is a good place to get the full picture before that conversation.